Compare Unicycive Therapeutics, Inc. (UNCY) vs ADMA Biologics, Inc. (ADMA) Stock

ADMA Biologics, Inc. (ADMA) offers the better valuation at 19.2x trailing P/E (16.3x forward), making it the more compelling value choice. Analysts rate Unicycive Therapeutics, Inc. (UNCY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Unicycive Therapeutics, Inc. is actually cheaper at 1.0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc. (ADMA) delivered a total return of +543.4%, compared to -86.1% for Unicycive Therapeutics, Inc. (UNCY). A $10,000 investment in ADMA five years ago would be worth approximately $64K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADMA returned +227.8% versus UNCY's -86.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Unicycive Therapeutics, Inc. (UNCY) is the lower-risk stock at 0.81β versus ADMA Biologics, Inc.'s 1.10β — meaning ADMA is approximately 36% more volatile than UNCY relative to the S&P 500. On balance sheet safety, Unicycive Therapeutics, Inc. (UNCY) carries a lower debt/equity ratio of 10% versus 24% for ADMA Biologics, Inc. — giving it more financial flexibility in a downturn.

ADMA Biologics, Inc. (ADMA) is the more profitable company, earning 46.4% net margin versus 0.0% for Unicycive Therapeutics, Inc. — meaning it keeps 46.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 32.6% versus 0.0% for UNCY. At the gross margin level — before operating expenses — ADMA leads at 51.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Unicycive Therapeutics, Inc. (UNCY) trades at 1.0x forward P/E versus 16.3x for ADMA Biologics, Inc. — 15.3x cheaper on a one-year earnings basis.

In this comparison, UNCY (2.4% yield) pays a dividend. ADMA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Unicycive Therapeutics, Inc. (UNCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.81), 2.4% yield). Both have compounded well over 10 years (UNCY: -86.1%, ADMA: +227.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. UNCY pays a dividend while ADMA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.